MRK.DE - Merck KGaA

XETRA - XETRA Delayed Price. Currency in EUR
-0.35 (-0.21%)
As of 01:46PM CEST. Market open.
Stock chart is not supported by your current browser
Previous close169.05
Bid168.65 x 6700
Ask168.70 x 11200
Day's range168.15 - 169.90
52-week range153.10 - 202.80
Avg. volume326,820
Market cap73.347B
Beta (5Y monthly)0.61
PE ratio (TTM)22.23
EPS (TTM)7.59
Earnings date03 Aug 2023
Forward dividend & yield2.20 (1.34%)
Ex-dividend date02 May 2023
1y target est203.50
  • Reuters

    CEO of Germany's Merck: decoupling from China would be at huge economic cost

    FRANKFURT (Reuters) -The CEO of German technology group Merck KGaA said that unravelling trade ties with China would come at great economic cost and she was banking on dialogue to ease tensions between Beijing and Western powers. Belen Garijo, the Spanish CEO of the German drugmaker and manufacturer of lab equipment and semiconductor chemicals, said late on Monday that dependencies between the powers were huge, speaking at a journalist club event in Frankfurt. For months, U.S. and German lawmakers have called for a reduction in trade to cut dependency on China.

  • Reuters

    Merck KGaA aims to build domestic supply chains in China

    German technology group Merck KGaA said it was determined to invest further in China and aims to build domestic supply chains there to curb imports of key raw materials amid rising tensions between Beijing and Western powers. "We are trying to limit, when it is reasonably possible, imports of important raw materials from other countries into China, especially from the U.S. into China," finance chief Marcus Kuhnert said on a media call on Thursday on first-quarter results. "At the same time we are creating a China-for-China approach, so that also the vast majority of products we are going to produce in China is actually supposed to be for the Chinese market," he added.

  • Reuters

    Germany's Merck flags decline in operating profit of up to 10% in 2023

    Germany's Merck KGaA on Thursday warned that adjusted operating earnings could decline by as much as 10% this year as the outlook for its specialty chemicals business darkened, offsetting an upswing in drug prescriptions. The company said it was expecting between 6.1 billion euros ($6.71 billion) and 6.7 billion euros in 2023 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs. It had previously predicted a "moderate decline to an about stable development", before any currency swings.

  • Zacks

    Profound Medical (PROF) Moves 9.4% Higher: Will This Strength Last?

    Profound Medical (PROF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

  • Reuters

    Merck KGaA expects 2023 profit to slip as COVID demand wanes

    Germany's Merck KGaA on Thursday predicted 2023 earnings would slip due to a decline at its electronic chemicals unit and a drop in COVID-related demand for its lab supplies from drug and vaccine makers. For 2023 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, the company "assumes a moderate decline to an about stable development", before any currency swings, it said in a statement. Negative foreign exchange effects would likely be an additional drag of between 1% and 4%, according to the maker of pharmaceuticals, lab equipment and specialty chemicals.

  • Zacks

    Bears are Losing Control Over Merck KGaA (MKGAF), Here's Why It's a 'Buy' Now

    Merck KGaA (MKGAF) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

  • Reuters

    Mersana signs deal with Merck KGaA for cancer therapy development

    Mersana would receive $30 million in an upfront payment, which would be used to develop drugs known as antibody-drug conjugates (ADCs), the company said. ADCs combine a tumor-seeking monoclonal antibody with a cell-killing chemotherapy payload, designed for a targeted destructive effect that, unlike conventional chemotherapy, spares healthy cells.

  • Reuters

    Merck KGaA in push to become twice as productive in drug development

    Germany's Merck KGaA on Monday said it aims to double the productivity of its research and development into oncology, neurology and immunology treatments. The company is holding an investor day on its healthcare research and development strategy on Monday.

  • Reuters

    Merck picks Goldman Sachs to launch pigments sale in 2023 – sources

    German diversified group Merck KGaA has tapped Goldman Sachs to revive a $1 billion sale of its pigments division after previous attempts to sell the business fell through during the pandemic, three sources told Reuters. The business, known as Surface Solutions, has already drawn interest from Austrian rival Heubach, owned by SK Capital Partners, one of the sources said, speaking on condition of anonymity. Surface Solutions makes pigments for a pearlescent or metallic shine in coatings, plastics and cosmetics and could be valued at about 1 billion euros ($1.03 billion), the sources said.

  • Reuters

    Merck KGaA says larger-scale acquisitions an option from 2023

    FRANKFURT (Reuters) -German diversified healthcare and chemicals group Merck KGaA said it would begin to look into larger takeover deals next year after having reduced its debt. The group's most recent major takeover was that of Versum Materials, a maker of chemicals for semiconductor production, for 5.8 billion euros ($5.7 billion) in 2019.

  • Reuters

    Merck KGaA profit gets boost from dollar, outweighing higher costs

    (Reuters) -Germany's Merck KGaA saw adjusted earnings rise 13.1% in the second quarter as higher revenues from its biotech lab equipment and its chemicals for semiconductor production were further bolstered by currency tailwinds. Second-quarter earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, rose to 1.78 billion euros ($1.81 billion), surpassing the average estimate of 1.71 billion in an analyst poll on the company's website. Adjusted EBITDA would have risen only 3.2% without the currency tailwinds.